A phase 1/2 trial of AVM0703 in advanced solid tumours, run by AVM Biotechnology Inc, now recruiting.
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies is a phase 1/2 interventional study registered as NCT04329728 by AVM Biotechnology Inc, with 144 participants planned, started 2020-11-06 and due to reach its primary completion in 2027-11-30. Interventions recorded: AVM0703.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.